Developed at the Stine Research Center, rimisoxafen is the first herbicide classified by the Global Herbicide Resistance Action Committee as a dual mode of action, specifically targeting groups 12 and 32. By inhibiting two distinct biochemical pathways, the product aims to slow the development of weed resistance, a growing concern for growers who spend over $6 billion annually on weed control. Extensive field testing has shown the herbicide is effective against Palmer amaranth and waterhemp, two of the most troublesome broadleaf weeds currently impacting U.S. soybean production.

Seva Rostovtsev, executive vice president and chief technology officer at FMC, noted that the submission follows a decade of biological research and over 1,000 field and greenhouse studies. This filing represents the third novel herbicide active ingredient the company has moved to the regulatory stage in recent years, following Isoflex and Dodhylex. While the U.S. is the initial target for the product, the company plans to pursue registrations in additional international markets. Rimisoxafen is not currently available for sale or use, and any future commercialization remains contingent upon successful regulatory review.